X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $1.50 target price on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $3.00 price target on shares of X4 Pharmaceuticals in a research report on Wednesday.

X4 Pharmaceuticals Stock Performance

XFOR opened at $0.27 on Thursday. The company has a market cap of $47.08 million, a price-to-earnings ratio of -3.01 and a beta of 0.39. The firm’s fifty day simple moving average is $0.44 and its two-hundred day simple moving average is $0.52. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 52-week low of $0.24 and a 52-week high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million. Equities analysts anticipate that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. This represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 202,663 shares of company stock worth $91,198. 1.62% of the stock is owned by insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Cantor Fitzgerald L. P. acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $30,000. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at about $30,000. Atria Wealth Solutions Inc. acquired a new position in X4 Pharmaceuticals in the fourth quarter valued at about $44,000. Wells Fargo & Company MN boosted its stake in X4 Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares during the period. Finally, Bank of America Corp DE increased its position in shares of X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.